High-density lipoprotein 3 cholesterol and primary open-angle glaucoma: metabolomics and mendelian randomization analyses.

[1]  Adriana I. Iglesias,et al.  Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries , 2021, Nature Communications.

[2]  Tom R. Gaunt,et al.  Triglyceride-containing lipoprotein sub-fractions and risk of coronary heart disease and stroke: A prospective analysis in 11,560 adults , 2020, European journal of preventive cardiology.

[3]  James R. Staley,et al.  A robust and efficient method for Mendelian randomization with hundreds of genetic variants , 2020, Nature Communications.

[4]  T. Wong,et al.  Singapore Chinese Eye Study: key findings from baseline examination and the rationale, methodology of the 6-year follow-up series , 2019, British Journal of Ophthalmology.

[5]  Ira M. Hall,et al.  Exome sequencing of Finnish isolates enhances rare-variant association power , 2019, Nature.

[6]  Stephen Burgess,et al.  A comparison of robust Mendelian randomization methods using summary data , 2019, bioRxiv.

[7]  Shiming Wang,et al.  Hyperlipidemia, Blood Lipid Level, and the Risk of Glaucoma: A Meta-Analysis. , 2019, Investigative ophthalmology & visual science.

[8]  Christine Binquet,et al.  Increased High-Density Lipoprotein Levels Associated with Age-Related Macular Degeneration: Evidence from the EYE-RISK and European Eye Epidemiology Consortia. , 2018, Ophthalmology.

[9]  D. Lawlor,et al.  Improving the accuracy of two-sample summary-data Mendelian randomization: moving beyond the NOME assumption , 2018, bioRxiv.

[10]  V. Salomaa,et al.  Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies , 2018, Alzheimer's & Dementia.

[11]  V. Salomaa,et al.  Cohort Profile: The National FINRISK Study. , 2018, International journal of epidemiology.

[12]  T. Lehtimäki,et al.  Circulating metabolites and the risk of type 2 diabetes: a prospective study of 11,896 young adults from four Finnish cohorts , 2019, bioRxiv.

[13]  N. Vuilleumier,et al.  Pharmacological Intervention to Modulate HDL: What Do We Target? , 2018, Front. Pharmacol..

[14]  R. Ritch,et al.  Glaucoma , 2017, The Lancet.

[15]  Fernando Pires Hartwig,et al.  Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption , 2017, bioRxiv.

[16]  T. Wong,et al.  Singapore Indian Eye Study‐2: methodology and impact of migration on systemic and eye outcomes , 2017, Clinical & experimental ophthalmology.

[17]  S. Thompson,et al.  Interpreting findings from Mendelian randomization using the MR-Egger method , 2017, European Journal of Epidemiology.

[18]  Karen L. Mohlke,et al.  The Metabolic Syndrome in Men study: a resource for studies of metabolic and cardiovascular diseases , 2017, Journal of Lipid Research.

[19]  G. Davey Smith,et al.  Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator , 2016, Genetic epidemiology.

[20]  G. Davey Smith,et al.  Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies1 , 2016, The American journal of clinical nutrition.

[21]  K. Park,et al.  Prevalence, Awareness, and Risk Factors of Primary Open-Angle Glaucoma: Korea National Health and Nutrition Examination Survey 2008-2011. , 2016, Ophthalmology.

[22]  Mervin Chávez-Castillo,et al.  Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics , 2015, Cholesterol.

[23]  Tin Aung,et al.  The Prevalence and Types of Glaucoma in an Urban Chinese Population: The Singapore Chinese Eye Study. , 2015, JAMA ophthalmology.

[24]  K. Rye,et al.  HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. , 2015, Circulation research.

[25]  Juan Zhang,et al.  Cholesterol metabolism and homeostasis in the brain , 2015, Protein & Cell.

[26]  Pasi Soininen,et al.  Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. , 2015, Circulation. Cardiovascular genetics.

[27]  T. Wong,et al.  Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. , 2014, Ophthalmology.

[28]  T. Wong,et al.  Common variants near ABCA1 and in PMM2 are associated with primary open-angle glaucoma , 2014, Nature Genetics.

[29]  Janey L. Wiggs,et al.  Common variants near ABCA1, AFAP1 and GMDS confer risk of primary open-angle glaucoma , 2014, Nature Genetics.

[30]  P. Visscher,et al.  Calculating statistical power in Mendelian randomization studies. , 2013, International journal of epidemiology.

[31]  Jingyuan Deng,et al.  Multi-dimensional Co-separation Analysis Reveals Protein–Protein Interactions Defining Plasma Lipoprotein Subspecies* , 2013, Molecular & Cellular Proteomics.

[32]  B. Pierce,et al.  Efficient Design for Mendelian Randomization Studies: Subsample and 2-Sample Instrumental Variable Estimators , 2013, American journal of epidemiology.

[33]  Yoshiro Saito,et al.  Plasma and serum from nonfasting men and women differ in their lipidomic profiles. , 2013, Biological & pharmaceutical bulletin.

[34]  G. Norata,et al.  High-Density Lipoprotein Subfractions - What the Clinicians Need to Know , 2013, Cardiology.

[35]  P. Mitchell,et al.  Singapore Malay Eye Study: rationale and methodology of 6‐year follow‐up study (SiMES‐2) , 2012, Clinical & experimental ophthalmology.

[36]  A. Kontush,et al.  Biological activities of HDL subpopulations and their relevance to cardiovascular disease. , 2011, Trends in molecular medicine.

[37]  C. Creuzot-Garcher,et al.  24S-hydroxycholesterol and cholesterol-24S-hydroxylase (CYP46A1) in the retina: from cholesterol homeostasis to pathophysiology of glaucoma. , 2011, Chemistry and physics of lipids.

[38]  Florian Kronenberg,et al.  Differences between Human Plasma and Serum Metabolite Profiles , 2011, PloS one.

[39]  G. D. Paolo,et al.  Linking lipids to Alzheimer's disease: cholesterol and beyond , 2011, Nature Reviews Neuroscience.

[40]  S. Reddy,et al.  HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms , 2011, Nature Reviews Cardiology.

[41]  C. Chien,et al.  Comparison of comorbid conditions between open-angle glaucoma patients and a control cohort: a case-control study. , 2010, Ophthalmology.

[42]  B. Nan,et al.  The relationship between components of metabolic syndrome and open-angle glaucoma. , 2010, Ophthalmology.

[43]  P. Mitchell,et al.  Methodology of the Singapore Indian Chinese Cohort (SICC) Eye Study: Quantifying ethnic variations in the epidemiology of eye diseases in Asians , 2009, Ophthalmic epidemiology.

[44]  Alkes L. Price,et al.  Reconstructing Indian Population History , 2009, Nature.

[45]  J. Lau,et al.  Systematic Review: Association of Low-Density Lipoprotein Subfractions With Cardiovascular Outcomes , 2009, Annals of Internal Medicine.

[46]  Leopold Schmetterer,et al.  Endothelial dysfunction in glaucoma , 2009, Acta ophthalmologica.

[47]  Peter Kraft,et al.  Curses--winner's and otherwise--in genetic epidemiology. , 2008, Epidemiology.

[48]  A. Tall,et al.  Cholesterol efflux pathways and other potential mechanisms involved in the athero‐protective effect of high density lipoproteins , 2008, Journal of internal medicine.

[49]  R. Collins,et al.  Newly identified loci that influence lipid concentrations and risk of coronary artery disease , 2008, Nature Genetics.

[50]  T. Wong,et al.  Rationale and Methodology for a Population-Based Study of Eye Diseases in Malay People: The Singapore Malay Eye Study (SiMES) , 2007, Ophthalmic epidemiology.

[51]  D. Cook,et al.  Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. , 2006, Investigative ophthalmology & visual science.

[52]  P. Foster,et al.  The definition and classification of glaucoma in prevalence surveys , 2002, The British journal of ophthalmology.

[53]  Richard R. Ernst,et al.  Nuclear Magnetic Resonance Fourier Transform Spectroscopy (Nobel Lecture) , 1992 .

[54]  R. Mensink,et al.  Determinants of cholesterol efflux capacity in humans. , 2018, Progress in lipid research.

[55]  Stefan Sperlich,et al.  Generalized Additive Models , 2014 .